Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies.
作者信息
Dasari Arvind, Grothey Axel, Kopetz Scott
机构信息
Arvind Dasari, The University of Texas MD Anderson Cancer Center, Houston, TX; Axel Grothey, The University of Tennessee West Cancer Center, Memphis, TN; and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX.
出版信息
J Clin Oncol. 2018 Oct 30;36(35):JCO2018789032. doi: 10.1200/JCO.2018.78.9032.
Abstract
摘要
相似文献
1
Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies.
J Clin Oncol. 2018 Oct 30;36(35):JCO2018789032. doi: 10.1200/JCO.2018.78.9032.
2
Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review).
Oncol Rep. 2023 May;49(5). doi: 10.3892/or.2023.8543. Epub 2023 Apr 13.
3
[Research progress on circulating tumor DNA as a biomarker for minimal residual disease in solid tumors].
Zhongguo Dang Dai Er Ke Za Zhi. 2023 Oct 15;25(10):1072-1077. doi: 10.7499/j.issn.1008-8830.2304040.
4
Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Int J Mol Sci. 2023 Jun 16;24(12):10230. doi: 10.3390/ijms241210230.
5
Minimal Residual Disease Monitoring in Radically Treated Non-Small Cell Lung Cancer: Challenges and Future Directions.
Onco Targets Ther. 2023 Apr 7;16:249-259. doi: 10.2147/OTT.S322242. eCollection 2023.
6
Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors.
Clin Cancer Res. 2019 Oct 15;25(20):6026-6034. doi: 10.1158/1078-0432.CCR-19-0152. Epub 2019 May 14.
7
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
JAMA Oncol. 2019 Dec 1;5(12):1710-1717. doi: 10.1001/jamaoncol.2019.3616.
8
Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review.
Front Genet. 2023 Aug 10;14:1172108. doi: 10.3389/fgene.2023.1172108. eCollection 2023.
9
Coexisting opportunities and challenges: In which scenarios can minimal/measurable residual disease play a role in advanced non-small cell lung cancer?
Chin J Cancer Res. 2021 Oct 31;33(5):574-582. doi: 10.21147/j.issn.1000-9604.2021.05.04.
10
Use of Circulating Tumor DNA to Monitor Minimal Residual Disease Among Patients With Colorectal Cancer.
Clin J Oncol Nurs. 2023 Jul 20;27(4):369-374. doi: 10.1188/23.CJON.369-374.
引用本文的文献
1
ctDNA and Recurrence Risk for Adjuvant De-Escalation in HPV-Positive Oropharyngeal Carcinoma: A Secondary Analysis of the DART Phase 3 Randomized Clinical Trial.
JAMA Otolaryngol Head Neck Surg. 2025 May 22. doi: 10.1001/jamaoto.2025.0903.
2
Shedding Light on the Prognostic and Predictive Value of Circulating Tumor DNA for Management of Patients with Early-Stage Colon Cancer.
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251317094. doi: 10.1177/15330338251317094.
3
Stool and blood biomarkers for colorectal cancer management: an update on screening and disease monitoring.
Mol Cancer. 2024 Nov 19;23(1):259. doi: 10.1186/s12943-024-02174-w.
4
Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease.
Nat Cancer. 2024 Oct;5(10):1534-1556. doi: 10.1038/s43018-024-00828-8. Epub 2024 Sep 20.
5
Hypermethylated SHOX2 in circulating cell-free DNA post renal cell carcinoma surgery as TNM-independent biomarker for recurrence risk.
Am J Transl Res. 2024 Jan 15;16(1):304-313. doi: 10.62347/QOBT7285. eCollection 2024.
6
Circulating tumor DNA analysis predicts recurrence and avoids unnecessary adjuvant chemotherapy in I-IV colorectal cancer.
Ther Adv Med Oncol. 2024 Jan 27;16:17588359231220607. doi: 10.1177/17588359231220607. eCollection 2024.
7
Detection of Glioma-Related Hotspot Mutations Through Sequencing of Cerebrospinal Fluid (CSF)-Derived Circulating Tumor DNA: A Pilot Study on CSF-Based Liquid Biopsy for Primary Spinal Cord Astrocytoma.
Neurospine. 2023 Jun;20(2):701-708. doi: 10.14245/ns.2346210.105. Epub 2023 Jun 30.
8
Clinical development of new drugs for adults and children with cancer, 2010-2020.
J Natl Cancer Inst. 2023 Aug 8;115(8):917-925. doi: 10.1093/jnci/djad082.
9
EMP1 tumor cells drive metastatic relapse.
Cell Res. 2023 May;33(5):337-338. doi: 10.1038/s41422-022-00769-w.
10
Role of myeloid-derived suppressor cells in tumor recurrence.
Cancer Metastasis Rev. 2023 Mar;42(1):113-142. doi: 10.1007/s10555-023-10079-1. Epub 2023 Jan 14.
本文引用的文献
1
The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis.
Medicine (Baltimore). 2018 Mar;97(13):e0197. doi: 10.1097/MD.0000000000010197.
2
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
J Clin Oncol. 2018 Jun 1;36(16):1631-1641. doi: 10.1200/JCO.2017.76.8671. Epub 2018 Mar 5.
3
Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study.
Gut. 2019 Apr;68(4):663-671. doi: 10.1136/gutjnl-2017-315852. Epub 2018 Feb 2.
4
Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.
Cancer Discov. 2017 Dec;7(12):1394-1403. doi: 10.1158/2159-8290.CD-17-0716. Epub 2017 Sep 24.
5
Going With the Flow: The Promise and Challenge of Liquid Biopsies.
JAMA. 2017 Sep 26;318(12):1095-1097. doi: 10.1001/jama.2017.10203.
6
Circulating Tumor DNA: Measurement and Clinical Utility.
Annu Rev Med. 2018 Jan 29;69:223-234. doi: 10.1146/annurev-med-041316-085721. Epub 2017 Aug 28.
7
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061. doi: 10.6004/jnccn.2017.0131.
8
Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer.
Clin Cancer Res. 2017 Sep 15;23(18):5437-5445. doi: 10.1158/1078-0432.CCR-17-0510. Epub 2017 Jun 9.
9
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364.
10
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Clin Cancer Res. 2017 Aug 1;23(15):3980-3993. doi: 10.1158/1078-0432.CCR-16-2895. Epub 2017 Apr 20.
Zotero 插件